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Fetal bovine serum (FBS) or other mammal-derived fac-
tors are extensively supplemented as growth factor into
culture medium. Since mammal-derived factors arouses
the concern about the risk of zoonosis, serum- and
mammal-free culture is strongly required. We focused
on sericin hydrolysates, originating from silkworm, and
reported that sericin is effective as growth factor to var-
ious cells. But it is not elucidated how sericin induces
the proliferation and inhibits apoptosis of the cells. In
this study, inhibitor assay was done in order to identify
signaling factors involved in sericin effect. In hybridoma
cells, the involvement of Src was suggested, while ERK1/
2, PP2A and p38 were not involved. In HepG2 cells, the
involvement of Src and ERK1/2 was suggested. From
these results, it was implied that the mitogenic effect of
sericin might be transduced through different pathways
depending on cell line.
Background
In in vitro cell culture, mammal-derived factors includ-
ing FBS are usually used as growth factors and supple-
mented into the media. However, supplementing
mammal-derived factors causes the concern about the
risk of zoonosis such as abnormal prions and various
viruses. Therefore, mammal-free culture is strongly
required in the industry of antibody therapeutics pro-
duction and in regenerative medicine including cell
therapy. As an alternative to mammal-derived factors,
we focused on hydrolysate of sericin, which is glue pro-
tein included in silk fiber. Our previous studies revealed
that sericin has mitogenic and anti-apoptotic effect on
various cell lines [1-3]. Additionally, sericin hydrolysates
treated with autoclave sterilization maintained its origi-
nal mitogeneic activity and so we successfully developed
a mammal-free medium, Sericin-GIT (Wako Pure Che-
mical Industries, Ltd., Japan). Although sericin is
effective, it is not revealed how sericin up-regulates the
proliferation and down-regulates apoptosis.
In the previous study, the following results were
obtained. One, cDNA microarray analysis detected up-
regulation of myc, tbp, fos and Bcl-xL, and down-regula-
tion of atf3 after sericin treatment. Two, Inhibition
assay confirmed the involvement of Ras and MEK1/2 in
the mitogenic effect of sericin. From these results, we
suppose a following pathway (Figure 1). In this study,
inhibitor assays against the factors shown in the figure
were done in order to identify signaling factors involved
in sericin effect.
Materials and methods
Cells. Mouse hybridoma 2E3-O cells and human hepa-
toblastoma HepG2 cells were cultured in ASF104 (Aji-
nomoto Japan) serum-free medium and DME medium
(Nissui, Japan) without FBS, respectively.
Inhibitors. PP2 (BioMoL, USA), ERK Activation Inhi-
bitor 1, Cell-Permeable (Calbiochem, USA), Okadaic
acid (Calbiochem), SB239063 (SIGMA, USA) were used
at inhibition assay.
Inhibition Assays. Mouse hybridoma 2E3-O cells and
human hepatoblastoma HepG2 cells were cultivated in
addition of each of inhibitors. After two days, the num-
ber of cells and the viability were determined by trypan
blue-exclusion test with hemocytometer.
Results
Inhibition assays were done in order to identify signaling
factors involved in sericin effect.
Since Ras and MEK1/2 are involved in Map kinase
pathway, PP2, a specific inhibitor against Src, was used.
PP2 successfully neutralized the mitogenic effect of seri-
cin, indicating that Src would be involved.
Involvement of ERK1/2 was tested by using ERK Acti-
vation Inhibitor 1. The inhibitor neutralized the mito-
genic effect in HepG2 cells, but did not in hybridoma
cells, suggesting that ERK1/2 w o u l db ei n v o l v e di n
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any medium, provided the original work is properly cited.Figure 1 The pathway deduced from our previous study. cDNA microarray analysis detected up-regulation of myc, tbp, fos,a n dBcl-xL,a n d
down-regulation of atf3 after sericin treatment. Inhibition assay confirmed the involvement of Ras and MEK1/2 in the mitogenic effect of sericin.
Figure 2 Different pathways depending on cell line.
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confirm that ERK1/2 is not involved in hybridoma cells,
inhibition assay against PP2A was done; the mitogenic
effect could be enhanced by inhibition of PP2A if
MAPK pathway would be involved in the mitogenic
effect of sericin. Inhibition against PP2A failed to
improve the proliferation of the hybridoma cells treated
with sericin, implying that PP2A would not be involved.
Further cDNA microarray analysis implied that several
other genes might be affected by sericin treatment.
Among the genes, myc and stat1 are the lower signaling
factors of p38 and so SB239063, a specific inhibitor
against p38, was tested. It failed to neutralize, indicating
that p38 would not be involved in the mitogenic effect
of sericin.
Conclusions
In hybridoma cells, Src was involved in the mitogenic
effect of sericin, while ERK1/2, PP2A and p38 were not,
suggesting that Src could activate other factors to trans-
duce signal of sericin. In HepG2 cells, the involvement
of Src and ERK1/2 was confirmed, suggesting that
MAPK pathway could be involved. From these results,
the mitogenic effect of sericin is transduced through dif-
ferent pathways depending on cell lines as shown in fig-
ure 2. Further study should be done to reveal the
involvement of these factors.
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